Pfizer takes $1.2B hit after assessing prospects of Seagen ADCs

[cafead]

via Pfizer has taken a $1.2 billion hit after reassessing the prospects of two antibody-drug conjugates it picked up in the Seagen buyout.

The Big Pharma reported the financial blow as part of $2.9 billion in intangible asset impairment charges in its fourth-quarter results.

article source